US · GKOS
Glaukos Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Aliso Viejo, CA 92672
- Website
- glaukos.com
Price · as of 2025-12-31
$140.22
Market cap 6.99B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $69.75 | -50.26% |
| Intrinsic Value(DCF) | $124.04 | -11.54% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $17.14 | $64.98 | $28,412.26 | $0.00 | $0.00 |
| 2016 | $46.02 | $358.86 | $4,136.26 | $4.25 | $8.95 |
| 2017 | $31.36 | $43.44 | $949.00 | $4.01 | $0.00 |
| 2018 | $66.03 | $385.96 | $178.19 | $3.12 | $0.00 |
| 2019 | $39.50 | $96.01 | $45.37 | $18.32 | $15.52 |
| 2020 | $88.85 | $111.69 | $2.17 | $0.00 | $0.00 |
| 2021 | $50.66 | $91.85 | $19.50 | $5.88 | $0.00 |
| 2022 | $45.36 | $83.09 | $0.59 | $0.00 | $0.00 |
| 2023 | $87.46 | $49.16 | $0.00 | $0.00 | $0.00 |
| 2024 | $104.19 | $60.84 | $0.05 | $0.00 | $0.00 |
| 2025 | $121.12 | $69.75 | $80.39 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Glaukos Corporation's (GKOS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $69.75
- Current price
- $140.22
- AI upside
- -50.26%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$124.04
-11.54% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GKOS | Glaukos Corporation | $140.22 | 6.99B | -50% | -12% | — | — | -51.83 | 10.56 | 13.65 | -45.16 | -281.48 | 15.48 | 55.72% | -39.33% | -36.99% | -18.78% | -36.24% | -14.31% | 0.21 | -43.06 | 4.69 | 3.82 | -0.32 | 1841.00% | 3233.00% | -2013.00% | -0.78% | -0.46 | -10.09% | 0.00% | 0.00% | 0.00% | -34.01 | -125.68 | 13.38 | 16.38 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| ALKS | Alkermes plc | $30.10 | 4.97B | +85% | -49% | -41% | -85% | 20.62 | 2.74 | 3.38 | 13.49 | — | 2.87 | 86.31% | 17.21% | 16.37% | 14.72% | 20.15% | 10.64% | 0.04 | 20.69 | 2.06 | 1.70 | -1.57 | -3410.00% | -525.00% | -9987.00% | 0.01% | 0.00 | 0.05% | 0.00% | 0.00% | 6.08% | 17.58 | 8571.26 | 3.02 | 5.27 |
| ARWR | Arrowhead Pharmaceuticals… | $63.27 | 8.86B | +5,558% | +96,147% | -95% | — | 272.90 | 17.63 | 9.91 | 46.50 | — | 17.90 | 97.12% | 11.86% | -0.20% | 9.24% | 42.67% | 2.39% | 0.79 | 1.10 | 4.86 | 4.74 | 0.85 | -9976.00% | 2325815.00% | -12596.00% | 1.91% | 0.92 | 116.49% | 0.00% | 0.00% | 7.42% | 77.94 | 48.86 | 9.24 | 5.43 |
| BLCO | Bausch + Lomb Corporation | $18.30 | 6.48B | +52% | -60% | — | — | -18.50 | 1.01 | 1.28 | 20.11 | -138.78 | -4.09 | 58.71% | 3.12% | -7.06% | -5.45% | 1.41% | -2.56% | 0.83 | 0.37 | 1.55 | 0.84 | 8.72 | 1333.00% | 647.00% | 1186.00% | -1.01% | 0.15 | -0.59% | 0.00% | 0.00% | 0.00% | 72.33 | -174.25 | 2.25 | 0.92 |
| BRKR | Bruker Corporation | $40.11 | 6.09B | -2% | -60% | -66% | — | 206.96 | 2.44 | 1.76 | 17.43 | — | -7.46 | 45.61% | 6.30% | -0.25% | 1.37% | 2.20% | 0.48% | 0.76 | 4.69 | 1.73 | 0.66 | 3.59 | -11974.00% | 208.00% | -6816.00% | 0.72% | 0.10 | 1.10% | 0.38% | 78.10% | 8.68% | 35.15 | 175.83 | 2.22 | 1.82 |
| IRTC | iRhythm Technologies, Inc… | $133.75 | 4.32B | -14% | +116% | — | — | -92.28 | 26.92 | 5.50 | -1074.06 | — | 27.07 | 70.57% | -4.93% | -5.96% | -36.57% | -12.43% | -4.57% | 4.79 | -2.80 | 4.63 | 4.34 | -124.89 | -6171.00% | 2624.00% | -21299.00% | 0.84% | 0.53 | 11.65% | 0.00% | 0.00% | 0.00% | -115.69 | 123.36 | 5.70 | 3.00 |
| MMSI | Merit Medical Systems, In… | $77.18 | 4.58B | +4% | -60% | -62% | -45% | 35.22 | 2.86 | 2.99 | 14.98 | 715.00 | 8.38 | 48.70% | 12.19% | 8.48% | 8.67% | 7.25% | 5.03% | 0.57 | 6.98 | 4.34 | 2.80 | 1.35 | 493.00% | 1175.00% | 1800.00% | 4.77% | 1.24 | 11.26% | 0.00% | 0.00% | 0.00% | 26.93 | 23.07 | 3.28 | 4.04 |
| OSCR | Oscar Health, Inc. | $13.64 | 3.54B | +238% | +3,520% | — | — | -8.28 | 3.75 | 0.31 | -0.28 | — | 3.75 | 14.38% | -3.39% | -3.79% | -44.49% | 23.17% | -7.93% | 0.44 | -22.52 | 0.95 | 0.91 | 5.99 | -186594.00% | 2750.00% | 1138.00% | 28.86% | 0.23 | -61.87% | 0.00% | 0.00% | 30.44% | -0.27 | 0.10 | 0.01 | 1.28 |
| TFX | Teleflex Incorporated | $122.06 | 5.39B | -20% | -55% | — | +315% | -6.06 | 1.76 | 2.75 | 17.49 | — | -7.79 | 56.24% | 2.94% | -45.45% | -24.47% | 1.35% | -12.90% | 0.06 | 0.58 | 2.54 | 0.95 | -0.64 | -146824.00% | -3461.00% | -9972.00% | 0.03% | 0.13 | 0.03% | 1.10% | -6.70% | 36.82% | 90.40 | 3659.08 | 2.66 | 2.01 |
| TMDX | TransMedics Group, Inc. | $145.26 | 4.96B | -12% | +2,727% | -71% | +68% | 26.26 | 10.56 | 8.25 | 33.53 | 6.87 | 10.87 | 59.92% | 17.93% | 31.43% | 54.24% | 25.12% | 20.33% | 0.99 | 7.88 | 7.14 | 6.41 | -0.13 | 38218.00% | 3713.00% | -26504.00% | 2.67% | 2.16 | 30.90% | 0.00% | 0.00% | 4.01% | 45.85 | 37.27 | 8.22 | 6.19 |
About Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
- CEO
- Thomas William Burns
- Employees
- 995
- Beta
- 0.70
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($124.04 ÷ $140.22) − 1 = -11.54% (DCF, example).